Clinical Trial Update: EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas [Phase 2]

View source ↗

Summary

Phase 2 study of EndoTAG-1 in combination with gemcitabine for locally advanced and/or metastatic pancreatic adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• EndoTAG-1
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: MediGene | Conditions: Adenocarcinoma, Metastasis | Phase 2 | Status: COMPLETED